487 related articles for article (PubMed ID: 10392898)
1. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer.
Caca K; Kolligs FT; Ji X; Hayes M; Qian J; Yahanda A; Rimm DL; Costa J; Fearon ER
Cell Growth Differ; 1999 Jun; 10(6):369-76. PubMed ID: 10392898
[TBL] [Abstract][Full Text] [Related]
2. Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion.
Faux MC; Ross JL; Meeker C; Johns T; Ji H; Simpson RJ; Layton MJ; Burgess AW
J Cell Sci; 2004 Jan; 117(Pt 3):427-39. PubMed ID: 14679305
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks AB; Morin PJ; Vogelstein B; Kinzler KW
Cancer Res; 1998 Mar; 58(6):1130-4. PubMed ID: 9515795
[TBL] [Abstract][Full Text] [Related]
4. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
5. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.
Tetsu O; McCormick F
Nature; 1999 Apr; 398(6726):422-6. PubMed ID: 10201372
[TBL] [Abstract][Full Text] [Related]
6. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer.
Park WS; Oh RR; Park JY; Lee SH; Shin MS; Kim YS; Kim SY; Lee HK; Kim PJ; Oh ST; Yoo NJ; Lee JY
Cancer Res; 1999 Sep; 59(17):4257-60. PubMed ID: 10485468
[TBL] [Abstract][Full Text] [Related]
7. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of monocyte chemotactic protein-3 by activated beta-catenin.
Fujita M; Furukawa Y; Nagasawa Y; Ogawa M; Nakamura Y
Cancer Res; 2000 Dec; 60(23):6683-7. PubMed ID: 11118053
[TBL] [Abstract][Full Text] [Related]
9. Identification of Tcf4 residues involved in high-affinity beta-catenin binding.
Omer CA; Miller PJ; Diehl RE; Kral AM
Biochem Biophys Res Commun; 1999 Mar; 256(3):584-90. PubMed ID: 10080941
[TBL] [Abstract][Full Text] [Related]
10. A common human skin tumour is caused by activating mutations in beta-catenin.
Chan EF; Gat U; McNiff JM; Fuchs E
Nat Genet; 1999 Apr; 21(4):410-3. PubMed ID: 10192393
[TBL] [Abstract][Full Text] [Related]
11. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
Furlong MT; Morin PJ
Gynecol Oncol; 2000 Apr; 77(1):97-104. PubMed ID: 10739697
[TBL] [Abstract][Full Text] [Related]
12. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters.
Gustavson MD; Crawford HC; Fingleton B; Matrisian LM
Mol Carcinog; 2004 Nov; 41(3):125-39. PubMed ID: 15457508
[TBL] [Abstract][Full Text] [Related]
13. Differential formation of beta-catenin/lymphoid enhancer factor-1 DNA binding complex induced by nitric oxide in mouse colonic epithelial cells differing in adenomatous polyposis coli (Apc) genotype.
Mei JM; Hord NG; Winterstein DF; Donald SP; Phang JM
Cancer Res; 2000 Jul; 60(13):3379-83. PubMed ID: 10910042
[TBL] [Abstract][Full Text] [Related]
14. A second protein kinase CK1-mediated step negatively regulates Wnt signalling by disrupting the lymphocyte enhancer factor-1/beta-catenin complex.
Hämmerlein A; Weiske J; Huber O
Cell Mol Life Sci; 2005 Mar; 62(5):606-18. PubMed ID: 15747065
[TBL] [Abstract][Full Text] [Related]
15. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC.
von Kries JP; Winbeck G; Asbrand C; Schwarz-Romond T; Sochnikova N; Dell'Oro A; Behrens J; Birchmeier W
Nat Struct Biol; 2000 Sep; 7(9):800-7. PubMed ID: 10966653
[TBL] [Abstract][Full Text] [Related]
16. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin.
Kolligs FT; Kolligs B; Hajra KM; Hu G; Tani M; Cho KR; Fearon ER
Genes Dev; 2000 Jun; 14(11):1319-31. PubMed ID: 10837025
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
Araki Y; Okamura S; Hussain SP; Nagashima M; He P; Shiseki M; Miura K; Harris CC
Cancer Res; 2003 Feb; 63(3):728-34. PubMed ID: 12566320
[TBL] [Abstract][Full Text] [Related]
18. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression.
Shih IM; Yu J; He TC; Vogelstein B; Kinzler KW
Cancer Res; 2000 Mar; 60(6):1671-6. PubMed ID: 10749138
[TBL] [Abstract][Full Text] [Related]
19. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.
Crawford HC; Fingleton BM; Rudolph-Owen LA; Goss KJ; Rubinfeld B; Polakis P; Matrisian LM
Oncogene; 1999 May; 18(18):2883-91. PubMed ID: 10362259
[TBL] [Abstract][Full Text] [Related]
20. Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line.
Maeda O; Usami N; Kondo M; Takahashi M; Goto H; Shimokata K; Kusugami K; Sekido Y
Oncogene; 2004 Jan; 23(4):964-72. PubMed ID: 14661054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
